Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Oat beta-glucan oral composition and application thereof

A technology of glucan and composition, applied in the field of oral oat beta-glucan composition, can solve the problems of oat beta-glucan having poor taste, poor mouthfeel, inability to fully swell active ingredients, limited physical properties, and the like, Achieve the effect of significantly regulating blood lipids, reducing low-density lipoprotein and serum cholesterol, and evenly distributed

Active Publication Date: 2018-09-14
珠海津之敦医药科技有限公司
View PDF9 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the limitations of the physical properties of oat β-glucan itself affect its efficacy
The suitable way to take oat β-glucan is to drink it with water, but oat β-glucan is a macromolecular polymer with a certain viscosity. After brewing with water, the dispersibility is poor and it is easy to form agglomerates. Some active ingredients cannot be fully swollen and cannot exert their maximum effect
In addition, the taste and taste of oat β-glucan are poor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oat beta-glucan oral composition and application thereof
  • Oat beta-glucan oral composition and application thereof
  • Oat beta-glucan oral composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Raw material ratio (weight percent):

[0036] Oat beta-glucan: 85%

[0037] Resistant Dextrin: 5%

[0038] Fructose-oligosaccharides: 10%.

[0039] Preparation:

[0040] Mix the three components evenly.

Embodiment 2

[0042] Raw material ratio (weight percent):

[0043] Oat beta-glucan: 87.5%

[0044] Resistant Dextrin: 7.5%

[0045] Fructooligosaccharides: 5%.

Embodiment 3

[0047] Raw material ratio (weight percent):

[0048] Oat beta-glucan: 75%

[0049] Resistant Dextrin: 10%

[0050] Fructooligosaccharides: 15%.

[0051] The beneficial effect of the prescription of the present invention is further illustrated by human body test data.

[0052] 1. Blood lipid-lowering effect test:

[0053] 1. Subject selection: 30 patients with hyperlipidemia who meet the following criteria:

[0054] (1) Age 32~74 years old, gender is not limited;

[0055] (2) The body mass index is within the range of 19~30kg / m2;

[0056] (3) The blood low-density lipoprotein cholesterol (LDL-C) level is between 3.38 mmol / L and 4.52 mmol / L;

[0057](4) Without lipid-lowering drug treatment or lipid-lowering drug withdrawal for 12 weeks;

[0058] (5) Pregnant women, breastfeeding women, those taking hormonal drugs, patients with severe chronic diseases, and patients in the withdrawal period after surgery were excluded.

[0059] Using a randomized parallel controlled tr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an oat beta-glucan oral composition and application thereof. The composition is prepared from the following raw materials in percentage by weight: 75-92.5 percent of oat beta-glucan, 2.5-10 percent of resistant dextrin and 5-15 percent of fructo-oligosaccharide. The dispersibility of oat beta-glucan can be remarkably improved by optimizing the formula, so that the oat beta-glucan can be sufficiently combined with water molecules, the viscosity of the oat beta-glucan can be sufficiently induced, the oat beta-glucan can be distributed in intestinal tracts more uniformly,the effects of reducing blood lipids and blood glucose can be improved, and the flavor and acceptance of products can be remarkably improved. Compared with pure oat beta-glucan, the composition has the effects of remarkably adjusting blood lipids, reducing low density lipoprotein and serum cholesterol and remarkably controlling blood glucose, and has an important meaning for preventing and treating cardiovascular and cerebrovascular diseases and diabetes mellitus.

Description

technical field [0001] The invention belongs to the technical field of food processing, and in particular relates to an oral oat beta-glucan composition and application thereof. Background technique [0002] Oat food has the effect of lowering blood fat and serum cholesterol, and has important effects on the prevention and treatment of cardiovascular and cerebrovascular diseases and diabetes. Among them, the active ingredient that plays a role in health care is β-glucan in oatmeal. [0003] The β-(1→3, 1→4) glucan in oats is referred to as oat β-glucan for short, which is a non-starch polysaccharide existing in oat endosperm and aleurone layer cell wall. It is a high molecular polymer formed by connecting monomer β-D-glucopyranose through β-(1→3) and β-(1→4) glycosidic bonds. Among them, the distribution of β-(1→3) and β-(1→4) glycosidic bonds is neither completely ordered nor fully ordered, mainly cellotriose or cellotetraose of β-(1→4) glucan , more than 85% of the oat ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A23L33/125A23L29/30A23P10/47
CPCA23L29/35A23L33/125A23P10/47A23V2002/00A23V2200/3262A23V2200/328A23V2200/16A23V2250/5034A23V2250/5114A23V2250/28
Inventor 李宁陈松杰杨伦
Owner 珠海津之敦医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com